These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 35798007)

  • 1. Household Secondary Attack Rates of SARS-CoV-2 Omicron Variant, South Korea, February 2022.
    Lim DS; Choe YJ; Man Kim Y; Lee SE; Jang EJ; Kim J; Park YJ
    Emerg Infect Dis; 2022 Aug; 28(8):1731-1734. PubMed ID: 35798007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serial Intervals and Household Transmission of SARS-CoV-2 Omicron Variant, South Korea, 2021.
    Song JS; Lee J; Kim M; Jeong HS; Kim MS; Kim SG; Yoo HN; Lee JJ; Lee HY; Lee SE; Kim EJ; Rhee JE; Kim IH; Park YJ
    Emerg Infect Dis; 2022 Mar; 28(3):756-759. PubMed ID: 35107418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARS-CoV-2 Delta Variant Breakthrough Infection and Onward Secondary Transmission in Household.
    Yi S; Kim JM; Choe YJ; Hong S; Choi S; Ahn SB; Kim M; Park YJ
    J Korean Med Sci; 2022 Jan; 37(1):e12. PubMed ID: 34981682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SARS-CoV-2 Secondary Attack Rates in Vaccinated and Unvaccinated Household Contacts during Replacement of Delta with Omicron Variant, Spain.
    López-Muñoz I; Torrella A; Pérez-Quílez O; Castillo-Zuza A; Martró E; Bordoy AE; Saludes V; Blanco I; Soldevila L; Estrada O; Valerio L; Roure S; Vallès X
    Emerg Infect Dis; 2022 Oct; 28(10):1999-2008. PubMed ID: 36037811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccine Effect on Household Transmission of Omicron and Delta SARS-CoV-2 Variants.
    Kim YC; Kim B; Son NH; Heo N; Nam Y; Shin A; Yang AJ; Kim MH; Kyong T; Kang E; Park YS; Kim H
    J Korean Med Sci; 2023 Jan; 38(1):e9. PubMed ID: 36593690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transmission characteristics and inactivated vaccine effectiveness against transmission of the SARS-CoV-2 Omicron BA.2 variant in Shenzhen, China.
    He X; Liao Y; Liang Y; Yu J; Gao W; Wan J; Liao Y; Su J; Zou X; Tang S
    Front Immunol; 2023; 14():1290279. PubMed ID: 38259438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccine Effectiveness against SARS-CoV-2 among Household Contacts during Omicron BA.2-Dominant Period, Japan.
    Ogata T; Tanaka H; Kon A; Sakaibori N; Tanaka E
    Emerg Infect Dis; 2024 Jul; 30(7):1430-1433. PubMed ID: 38916601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis - California and New York, May-November 2021.
    León TM; Dorabawila V; Nelson L; Lutterloh E; Bauer UE; Backenson B; Bassett MT; Henry H; Bregman B; Midgley CM; Myers JF; Plumb ID; Reese HE; Zhao R; Briggs-Hagen M; Hoefer D; Watt JP; Silk BJ; Jain S; Rosenberg ES
    MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):125-131. PubMed ID: 35085222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postacute symptoms 4 months after SARS-CoV-2 infection during the Omicron period: a nationwide Danish questionnaire study.
    Spiliopoulos L; Sørensen AIV; Bager P; Nielsen NM; Hansen JV; Koch A; Meder IK; Videbech P; Ethelberg S; Hviid A
    Am J Epidemiol; 2024 Aug; 193(8):1106-1114. PubMed ID: 37981717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Community Transmission of SARS-CoV-2 Omicron Variant, South Korea, 2021.
    Kim EY; Choe YJ; Park H; Jeong H; Chung JH; Yu J; Ko HP; Ahn HJ; Go MY; Lee JH; Kim WI; Lee BS; Kim S; Yu M; Kim J; Lee HR; Jang EJ; Lee JJ; Lee HY; Kim JM; Choi JH; Lee SE; Kim IH; Park AK; Rhee JE; Kim EJ; Lee S; Park YJ
    Emerg Infect Dis; 2022 Apr; 28(4):898-900. PubMed ID: 35171760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COVID-19-Associated Hospitalizations Among Adults During SARS-CoV-2 Delta and Omicron Variant Predominance, by Race/Ethnicity and Vaccination Status - COVID-NET, 14 States, July 2021-January 2022.
    Taylor CA; Whitaker M; Anglin O; Milucky J; Patel K; Pham H; Chai SJ; Alden NB; Yousey-Hindes K; Anderson EJ; Teno K; Reeg L; Como-Sabetti K; Bleecker M; Barney G; Bennett NM; Billing LM; Sutton M; Talbot HK; McCaffrey K; Havers FP;
    MMWR Morb Mortal Wkly Rep; 2022 Mar; 71(12):466-473. PubMed ID: 35324880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants.
    Accorsi EK; Britton A; Fleming-Dutra KE; Smith ZR; Shang N; Derado G; Miller J; Schrag SJ; Verani JR
    JAMA; 2022 Feb; 327(7):639-651. PubMed ID: 35060999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SARS-CoV-2 Breakthrough Infections after introduction of 4 COVID-19 Vaccines, South Korea, 2021.
    Yi S; Choe YJ; Kim J; Kim YY; Kim RK; Jang EJ; Lim DS; Byeon HR; Lee S; Park E; Kim SJ; Park YJ
    Emerg Infect Dis; 2022 Mar; 28(3):753-756. PubMed ID: 35202529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.
    Thompson MG; Natarajan K; Irving SA; Rowley EA; Griggs EP; Gaglani M; Klein NP; Grannis SJ; DeSilva MB; Stenehjem E; Reese SE; Dickerson M; Naleway AL; Han J; Konatham D; McEvoy C; Rao S; Dixon BE; Dascomb K; Lewis N; Levy ME; Patel P; Liao IC; Kharbanda AB; Barron MA; Fadel WF; Grisel N; Goddard K; Yang DH; Wondimu MH; Murthy K; Valvi NR; Arndorfer J; Fireman B; Dunne MM; Embi P; Azziz-Baumgartner E; Zerbo O; Bozio CH; Reynolds S; Ferdinands J; Williams J; Link-Gelles R; Schrag SJ; Verani JR; Ball S; Ong TC
    MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):139-145. PubMed ID: 35085224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SARS-CoV-2 B.1.1.529 (Omicron) Variant Transmission Within Households - Four U.S. Jurisdictions, November 2021-February 2022.
    Baker JM; Nakayama JY; O'Hegarty M; McGowan A; Teran RA; Bart SM; Mosack K; Roberts N; Campos B; Paegle A; McGee J; Herrera R; English K; Barrios C; Davis A; Roloff C; Sosa LE; Brockmeyer J; Page L; Bauer A; Weiner JJ; Khubbar M; Bhattacharyya S; Kirking HL; Tate JE
    MMWR Morb Mortal Wkly Rep; 2022 Mar; 71(9):341-346. PubMed ID: 35238860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum Neutralization of SARS-CoV-2 Omicron BA.1 and BA.2 after BNT162b2 Booster Vaccination.
    Pedersen RM; Bang LL; Madsen LW; Sydenham TV; Johansen IS; Jensen TG; Justesen US; Andersen TE
    Emerg Infect Dis; 2022 Jun; 28(6):1274-1275. PubMed ID: 35356875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of SARS-CoV-2 vaccines on Covid-19 incidence and mortality in the United States.
    Fang F; Clemens JD; Zhang ZF; Brewer TF
    PLoS One; 2024; 19(4):e0301830. PubMed ID: 38656933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of the Bivalent mRNA COVID-19 Vaccine for Preventing Critical Infection From the SARS-CoV-2 Omicron Variant in the Republic of Korea.
    Choi YS; Ryu S; Kim RK; Chiara A; Baek S; Nam H; Park E; Kim EK; Choe YJ; Kwon D; Choi WS
    J Korean Med Sci; 2024 Sep; 39(37):e258. PubMed ID: 39355951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transmission Dynamics of the Delta Variant of SARS-CoV-2 Infections in South Korea.
    Hwang H; Lim JS; Song SA; Achangwa C; Sim W; Kim G; Ryu S
    J Infect Dis; 2022 Mar; 225(5):793-799. PubMed ID: 34865022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current evidence on efficacy of COVID-19 booster dose vaccination against the Omicron variant: A systematic review.
    Chenchula S; Karunakaran P; Sharma S; Chavan M
    J Med Virol; 2022 Jul; 94(7):2969-2976. PubMed ID: 35246846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.